Navigation Links
Genesis Biopharma Expresses Support for FDA Codevelopment Guidelines

MANHATTAN BEACH, Calif., Jan. 24, 2011/PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced the company's support of the FDA's newly drafted "Guidance for Industry Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination." This guidance document, designed to encourage companies to collaborate and seek approval for successfully developed drug combinations, would support Genesis Biopharma's development of its anti-CD55 monoclonal antibody shown to have potentially broad application as a targeted cancer therapy.  

In particular, this guidance would help enable the company's goal to form partnerships with pharmaceutical and biotechnology companies and to support clinical development efforts for their anti-CD55 monoclonal antibody.

"Genesis Biopharma's anti-CD55 program has the potential to expand and improve the clinical utility of already approved antibody therapies as well as some novel agents in development," said Robert Brooke, Genesis Biopharma President and CEO. "When this FDA guidance is finalized and approved, it will simplify efforts to form codevelopment partnerships and will ultimately ensure timely access to new and effective treatments for patients fighting currently sub-optimally treated conditions, such as metastatic cancer."  

"The regulatory professionals now have a much needed tool to guide companies when developing combinations of two investigational products toward the much needed goal of making available safe and effective therapies," added Dr. Hana B. Moran of Moran Advisors, LLC.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies.  For more information on the company, visit

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biopharma Raises $845,000 in Private Financings
2. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
3. Genesis Biopharma Announces $700K Private Financing
4. ThermoGenesis Announces Sale of BioArchive Systems In Asia as Company Increases Presence In Key Market
5. American Medical Systems and Tissue Genesis Sign $1.1 Million Collaboration Deal
6. Organogenesis CEO Geoff MacKay and COO / CFO Gary Gillheeney Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winners in New England
7. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
8. Thermogenesis Corp. to Announce First Quarter Fiscal 2010 Results on November 5, 2009
9. Dr. Damien Bates of Organogenesis Speaks on Regenerative Medicine for Opening Night of TEDMED Conference
10. ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
11. ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
Post Your Comments:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... their findings on what they believe could be a new and helpful biomarker ... new research. Click here to read it now. , Biomarkers are ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks , ... industrial engineering, was today awarded as one of ... of the world,s most innovative companies. Ginkgo Bioworks ... for the real world in the nutrition, health ... work directly with customers including Fortune 500 companies ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
Breaking Biology Technology:
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
(Date:6/9/2016)... 9, 2016 Paris Police ... video security solution to ensure the safety of people and ... during the major tournament Teleste, an international technology ... services, announced today that its video security solution will be ... back up public safety across the country. The system roll-out ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
Breaking Biology News(10 mins):